A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Inclusion Criteria:

• Participants who have completed the Treatment Period in a prior APG777 study andwere, in the Investigator's opinion, compliant with the study protocol

• Participants who, in the Investigator's opinion, would benefit from long-termtreatment with APG777

• Use the same non-prescription non-medicated emollient/moisturizer of their choicefrom the last day of the Parent Study and throughout the LTE study

Exclusion Criteria:

• Participants who have developed an AE while participating in the Parent Study.which, in the opinion of the Investigator or of the Medical Monitor, could indicatethat continued treatment with APG777 may present an unreasonable risk for thepatient

• Participants who terminated early from the Parent Study or permanently discontinuedthe study drug during the Parent Study

• Use of any of the prohibited medications in the Parent Study through Screening Visit (Visit 1) of the LTE study

• Presence of dermatologic conditions and/or comorbidities that might confound thediagnosis of AD and/or interfere with study assessments

Note: Additional protocol defined Inclusion/Exclusion criteria may apply